



Activation and Retention: A Magnetic Resonance Probe for the Detection of Acute Thrombosis**

Galen S. Loving and Peter Caravan*

Abstract: Blood-clot formation that results in the complete occlusion of a blood vessel (thrombosis) often leads to serious life-threatening events, such as strokes and heart attacks. As the composition of a thrombus changes as it matures, new imaging methods that are capable of distinguishing new clots from old clots may yield important diagnostic and prognostic information. To address this need, an activatable magnetic resonance (MR) probe that is responsive to a key biochemical process associated with recently formed clots has been developed.


New thrombi differ from mature thrombi in a variety of ways. They contain a host of enzymatic activities, including those responsible for the clotting cascade, and various types of leukocytes; they also contain activated platelets, which play an important role in mediating both thrombus formation and the wound-healing process.^[1,2] When platelets become activated, they aggregate to form a hemostatic plug at the clot site. This aggregation process is facilitated by integrins that are located on the surface of activated platelets. Integrins can bind fibrinogen with high affinity only after being triggered by the enzymatic activity of protein disulfide isomerase (PDI).^[3]

PDI is a protein-folding chaperone that typically resides in the lumen of the endoplasmic reticulum.^[4] However, some extracellular sources have also been reported, including the exterior surface of platelets.^[5] Studies have shown that upon platelet activation, surface-associated PDI undergoes a shift in the oxidation state of active-site cysteine residues favoring the enzymatically active reduced form.^[6] The fact that PDI activity is present on the surface of activated platelets could make it a useful biomarker of nascent blood clots. Therefore, we have designed a magnetic resonance (MR) imaging probe that takes advantage of this unique chemistry.

The native concentration of enzymes such as PDI is often too low for detection by MR probes by direct targeting. However, there are numerous examples of activatable MR probes that sense enzymatic activity.^[7] These probes undergo modification by the enzyme, which changes the relaxivity of the probe: This can be due to a change in the

hydration state^[8] or a change in the rotational correlation time of the molecule.^[9] A challenge remains in keeping the probe localized at the site of activation long enough for imaging. For instance, Miserus et al. addressed this issue by exploiting the enzymatic activity of the transglutaminase FXIIIa, which covalently attached a gadolinium-based MR probe directly to fibrin.^[10]

Herein, we describe a PDI-activatable probe for the detection of fresh blood clots that is retained in the clot through non-covalent binding to fibrin upon activation. This method builds on the properties of the previously reported fibrin-imaging probe EP-2104R (Scheme 1), which selectively



Scheme 1. Structures of the fibrin imaging probe EP-2104R and the mixed disulfide **1**, which can be converted into EP-2104R through the enzymatic activity of PDI. Compound **2** is a non-binding analogue of **1** that is not a substrate for PDI and serves as a negative control.

binds to fibrin with high affinity (10^6 – 10^7 M⁻¹), thus providing strong signal enhancement to the region because of its four attached gadolinium chelates.^[11] EP-2104R was shown to provide persistent clot enhancement in animal models and in human clinical trials.^[12] However, it cannot distinguish new clots from older more stable clots. We have prepared compound **1**, a non-binding precursor of EP-2104R that can be activated by PDI.

EP-2104R contains a key disulfide bond between two cysteine residues that is required for binding. The presence of this bond helps to preorganize many of the dihedral angles of the peptide macrocycle and gives rigidity to the overall structure. Previous studies in our laboratory have demonstrated that any modification to EP-2104R that prevents disulfide formation between these two cysteine residues

[*] G. S. Loving, Prof. P. Caravan
A. A. Martinos Center for Biomedical Imaging
Massachusetts General Hospital, Harvard Medical School
149 Thirteenth Street, Suite 2301, Charlestown, MA 02129 (USA)
E-mail: caravan@nmr.mgh.harvard.edu

[**] The National Institutes of Health are acknowledged for funding to P.C. (HL109448) and G.S.L. (CA009502) and instrumentation grants (RR023385, EB015896). Chris Farrar is thanked for help with the MRI experiment.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/ange.201308607>.




Figure 1. Mechanism of probe activation and retention at the clotting site. The PDI activity that is expressed on the surface of activated platelets in newly formed thrombi catalyzes the conversion of compound **1** into EP-2104R, which then binds neighboring fibrin with high affinity.

blocks binding to fibrin.^[13] We decided to exploit this feature by appending cystamine groups to both of the cysteine side chains to prevent cyclization until the probe encounters PDI (Figure 1). We expect the probe to be converted into EP-2104R by PDI on the platelet, so that the modified probe will then be selectively retained in the clot by binding to fibrin. Older clots, which no longer possess high PDI activity, will not show retention of the probe.

The activatable probe **1** was prepared from EP-2104R by reduction of the disulfide bond with tris(2-carboxyethyl)-phosphine (TCEP), followed by reoxidation to the mixed disulfide in the presence of a concentrated cystamine solution. Compound **1** was isolated in 46% overall yield after purification by HPLC (for details, see the Supporting Information).

To confirm that PDI does catalyze the cyclization reaction that converts **1** into EP-2104R, we monitored the reaction by HPLC (Figure 2). As PDI must remain in its reduced form to be active, a thiol cofactor, in this case dithiothreitol (DTT), is required. We observed quantitative conversion of **1** into EP-2104R in under 15 min at room temperature, whereas only 24% conversion was observed in the presence of DTT alone,




Figure 2. A series of HPLC traces showing the extent of conversion of compound **1** (40 μM) into EP-2104R after 15 min under four different reaction conditions: untreated (no enzyme or DTT added; —); with PDI (4 mg L^{-1} ;); with DTT (40 μM ; ---); and with both PDI (4 mg L^{-1}) and DTT (40 μM ; - - -).

and no conversion was observed when PDI was added without DTT.

Next, the affinity of **1** for fibrin was investigated for comparison to EP-2104R. This was done using a displacement assay where the fluorescence polarization of a fibrin-binding peptide (TRITC-Tn6) is measured in the presence of a competitor.^[13b,14] Here, we used a soluble fragment of fibrin that is termed DD(E). EP-2104R can displace the fluorescent peptide, which results in a large decrease in fluorescence anisotropy (Figure 3a), allowing us to calculate a K_d value of




Figure 3. Binding of probes to DD(E) (2 μM) is detected by measuring the decrease in fluorescence anisotropy that occurs upon competitive displacement of the TRITC-Tn6 probe (0.1 μM). a) EP-2104R (○) exhibits a strongly dose-dependent response, whereas **1** (●) does not. b) The conversion of **1** (10 μM) into EP-2104R is followed in real time by observing the displacement of TRITC-Tn6 from DD(E). The reaction was run under four different reaction conditions: untreated (○); PDI (1 mg L^{-1} ; ●); DTT (10 μM ; △); and DTT (10 μM) with PDI (1 mg L^{-1} ; ◆).

0.16 μM for EP-2104R. However, **1** shows virtually no competitive displacement of the TRITC-Tn6 probe across the same concentration range, which indicates that the dissociation constant for **1** must be at least 1000 times greater than that of EP-2104R.

The cyclization reaction can be followed in real time using the same displacement assay. As **1** undergoes conversion into EP-2104R, binding to DD(E) and displacement of the fluorescent peptide occurs. The reaction was run under a variety of conditions (Figure 3b). Conversion of **1** proceeds rapidly when both PDI and DTT are present at the same time, compared to when DTT alone is added. This indicates that the

probe is recognized as a substrate by PDI. As expected, no conversion of the probe was observed in the presence of PDI alone. Similar behavior was observed when the reaction was followed by relaxometry (see the Supporting Information).

The relaxivities of EP-2104R, **1**, and **2** are similar in the absence of DD(E). However, the relaxivity of EP-2104R is increased by more than 70 % in the presence of excess DD(E) (Table 1), exhibiting a value similar to its relaxivity reported

Table 1: Relaxivities per molecule ($\text{mM}^{-1} \text{s}^{-1}$) of probes that were measured in the presence and absence of DD(E) at 60 MHz, 37°C, TBS.

Compound	r_1 without DD(E) ^[b]	r_1 with DD(E) ^[c]	Increase with DD(E) [%]
EP-2104R	38.2 ± 0.9	65.8 ± 3.4	72
1	38.6 ± 0.7	40.8 ± 1.4	6
2	35.1 ± 1.1	35.0 ± 1.1	0

[b] Probe concentration: 20 μM –100 μM . [c] Probe concentration: 5 μM –25 μM ; DD(E) concentration: 30.5 μM . TBS = Tris-buffered saline (pH 7.8).

in fibrin.^[11] This increase is due to the longer rotational correlation time of the protein-bound probe. By contrast, the relaxivities of **1** and **2** show no increase in the presence of DD(E).

Three sets of phantoms were prepared and imaged at 1.5 T to illustrate how PDI-catalyzed activation of the mixed disulfide probe **1** leads to fibrin binding (Figure 4). Each phantom contained a series of glass inserts immersed in water. The first insert located on the far left of each phantom contained a solution of human fibrinogen (12.4 μM) and served as a signal reference for the other inserts. The remaining inserts contained solutions of either **1**, EP-2104R, or **2** and are displayed from left to right. For each compound,




Figure 4. T1-weighted MR images of phantoms 1–3 obtained at 1.5 T. Solutions of **1**, EP-2104R, and **2** that were treated with both PDI and DTT (+) are paired with solutions that were not treated (–). The probe-containing solutions of phantoms 2 and 3 were treated with thrombin and CaCl_2 to clot the fibrinogen. The inserts of phantom 3 were centrifuged to pellet the clots.

a single stock solution was divided into two separate fractions. One fraction was treated with a combination of both PDI and DTT for 30 min, whereas the second fraction was not. These solutions were then mixed with human fibrinogen to give a final fibrinogen concentration of 12.4 μM . The final probe concentration for each insert was 10 μM .

Phantom 2 contained the same solutions as phantom 1, except that these solutions were treated with thrombin and CaCl_2 , which converted the soluble fibrinogen into a homogeneous insoluble fibrin clot (Figure 4). The solutions of phantom 3 were the same as for phantom 2 except that the inserts were then centrifuged at high speed to pellet the clotted fibrin to leave a clear supernatant layer above.

In both phantoms 1 and 2, the signal enhancement from each probe was uniformly distributed throughout each of the inserts. By contrast, phantom 3 clearly showed that when compound **1** was treated with both PDI and DTT, the signal enhancement co-localized with the fibrin pellet, just as EP-2104R did independent of the treatment conditions. Likewise, when **1** was not treated with PDI and DTT, the distribution of the signal enhancement remained uniform throughout the sample as previously seen for compound **2**, which can neither bind fibrin nor be activated by PDI.

The binding of EP-2104R to fibrin was also marked by a measurable increase in signal enhancement because of the change in relaxivity that is associated with a decreased rotational correlation time. We compared the signal intensity ratio (SIR) between a given sample and the fibrinogen reference sample. The SIRs for each of the inserts of phantom 1 were then used to calculate the percentage change in signal intensity ratio ($\% \Delta \text{SIR}$) observed for the corresponding inserts of phantoms 2 and 3 (Supporting Information, Tables S4 and S5). When treated with PDI and DTT, compound **1** in phantom 2 exhibited a 12 % increase in SIR compared to only 3 % for the untreated sample. This difference was consistent with the values measured for the positive and negative fibrin-binding probes, EP-2104R and **2**.

The present form of **1** offers a number of properties that make it an attractive candidate for use in the identification and imaging of nascent blood clots. It is a suitable substrate for an enzyme that is uniquely expressed on the surface of activated platelets, and its enzyme-activated product binds fibrin selectively with an affinity that is 1000 times greater than that of the precursor. This activation and retention mechanism provides a high degree of specificity, as it depends on two distinct biomarkers of the associated pathology. The four attached gadolinium chelates also provide high relaxivity, which is enhanced by a further 70 % upon binding to the target. Therefore, the efficacy of this probe will most likely be dictated by the amount of PDI activity that is present and accessible to the probe in newly forming clots, which in turn will depend on the number of activated platelets present. In the absence of PDI (old clot), only a minute amount of the probe will be retained at the clot site, making detection difficult. A potential limitation for the current probe design is the observed background activation that occurs slowly over time in the presence of free thiols, including reduced glutathione and cysteine, which are known to be present in the blood at low micromolar concentrations.^[15] This could

result in collateral accumulation of the probe at older clot sites where activated platelets are no longer present, thereby yielding a false positive response. However, this process may be slow compared to the rate of systemic elimination of the probe from the body. Future work is required to optimize the form of the mixed disulfide for rapid reaction with PDI, but slow reaction with endogenous thiols.

Received: October 2, 2013

Published online: December 11, 2013

Keywords: disulfide bonds · enzymatic activation · fibrin · imaging agents · magnetic resonance imaging

- [1] J. Silvain, J. P. Collet, C. Nagaswami, F. Beygui, K. E. Edmondson, A. Bellemain-Appaix, G. Cayla, A. Pena, D. Brugier, O. Barthelemy, G. Montalescot, J. W. Weisel, *J. Am. Coll. Cardiol.* **2011**, 57, 1359.
- [2] A. T. Nurden, P. Nurden, M. Sanchez, I. Andia, E. Anitua, *Front. Biosci.* **2008**, 13, 3532.
- [3] D. W. Essex, *Antioxid. Redox Signaling* **2004**, 6, 736.
- [4] B. Wilkinson, H. F. Gilbert, *Biochim. Biophys. Acta Proteins Proteomics* **2004**, 1699, 35.
- [5] a) D. W. Essex, K. Chen, M. Swiatkowska, *Blood* **1995**, 86, 2168; b) C. Turano, S. Coppari, F. Altieri, A. Ferraro, *J. Cell. Physiol.* **2002**, 193, 154.
- [6] J. K. Burgess, K. A. Hotchkiss, C. Suter, N. P. Dudman, J. Szollosi, C. N. Chesterman, B. H. Chong, P. J. Hogg, *J. Biol. Chem.* **2000**, 275, 9758.
- [7] a) J. L. Major, T. J. Meade, *Acc. Chem. Res.* **2009**, 42, 893; b) B. Yoo, M. D. Pagel, *Front. Biosci.* **2008**, 13, 1733.
- [8] A. Y. Louie, M. M. Huber, E. T. Ahrens, U. Rothbacher, R. Moats, R. E. Jacobs, S. E. Fraser, T. J. Meade, *Nat. Biotechnol.* **2000**, 18, 321.
- [9] A. L. Nivorozhkin, A. F. Kolodziej, P. Caravan, M. T. Greenfield, R. B. Lauffer, T. J. McMurphy, *Angew. Chem.* **2001**, 113, 2987; *Angew. Chem. Int. Ed.* **2001**, 40, 2903.
- [10] R. J. Miserus, M. V. Herias, L. Prinzen, M. B. Lobbes, R. J. Van Suylen, A. Dirksen, T. M. Hackeng, J. W. Heemskerk, J. M. van Engelshoven, M. J. Daemen, M. A. van Zandvoort, S. Heeneman, M. E. Kooi, *JACC Cardiovasc. Imaging* **2009**, 2, 987.
- [11] K. Overoye-Chan, S. Koerner, R. J. Looby, A. F. Kolodziej, S. G. Zech, Q. Deng, J. M. Chasse, T. J. McMurphy, P. Caravan, *J. Am. Chem. Soc.* **2008**, 130, 6025.
- [12] a) R. Uppal, I. Ay, G. Dai, Y. R. Kim, A. G. Sorensen, P. Caravan, *Stroke* **2010**, 41, 1271; b) J. Vymazal, E. Spuentrup, G. Cardenas-Molina, A. J. Wiethoff, M. G. Hartmann, P. Caravan, E. C. Parsons, Jr., *Invest. Radiol.* **2009**, 44, 697.
- [13] a) R. Uppal, Z. Medarova, C. T. Farrar, G. Dai, A. Moore, P. Caravan, *Invest. Radiol.* **2012**, 47, 553; b) A. F. Kolodziej, S. A. Nair, P. Graham, T. J. McMurphy, R. C. Ladner, C. Wescott, D. J. Sexton, P. Caravan, *Bioconjugate Chem.* **2012**, 23, 548.
- [14] K. L. Ciesienski, Y. Yang, I. Ay, D. B. Chonde, G. S. Loving, T. A. Rietz, C. Catana, P. Caravan, *Mol. Pharmaceutics* **2013**, 10, 1100.
- [15] R. Banerjee, *J. Biol. Chem.* **2012**, 287, 4397.